About evoxx technologies Exit

evoxx technologies GmbH, a German Industrial Biotechnology Company, is focusing on the development and production of industrial enzymes and novel carbohydrate ingredients produced by enzymatic bioconversion. With its proprietary enzymes and carbohydrate ingredients, evoxx is active in high growth markets addressing consumer needs in the Global Food Health & Wellness Sector and Consumer Products Markets. Product development is based on the proprietary technology and patent platform covering the whole value chain from early enzyme and process development to industrial scale production and product deregulation. evoxx industrial partners and customers benefit from the unique metagenomics libraries, the enzyme and carbohydrate development skills and tech-transfer and production capabilities. evoxx is located on the Creative Campus in Monheim am Rhein and on the Biotech Campus Hermannswerder in Potsdam.

Press releases

1. August 2017

Specialty biotech company Advanced Enzymes acquires HTGF Portfolio company evoxx technologies

The industrial biotechnology company evoxx technologies GmbH has become a part of the leading specialty biotech company Advanced Enzyme Technologies Limited. Both companies announced that they have entered into a binding agreement about the acquisition of 100% stake in evoxx technologies. evoxx technologies is proud to announce that it will become part of the global enzyme manufacturing company Advanced Enzyme Technologies Limited. evoxx and its team of 35+ scientists & technicians across
24. June 2013

evocatal draws two new investors as it closes €3.5m Series B round

evocatal GmbH has completed a Series B financing round. All of the company’s existing investors took part, along with new investors NRW.BANK and LANXESS. In realizing the next step of its growth strategy, Düsseldorf-based enzyme specialist evocatal has partnered with two new investors: specialty chemicals company LANXESS and the NRW.BANK. The investments from this round of financing will be used to extend the firm’s technology platform as well as its product portfolio. “We will signifi
6. July 2010

evocatal GmbH Closes New Financing Round

evocatal GmbH, based in the Life Science Center Düsseldorf, has closed € 2 million in growth financing. Thus the industrial biotech company puts itself in a position to continue successfully started projects rigorously to market readiness. The current financing round is chaired by new investor Roland Oetker, who, together with existing investors High-Tech Gründerfonds (HTGF), Sirius Seedfonds Düsseldorf (SSFD) and business angel Prof. Riesner, provides € 2 million in growth capital. Fo

Info & Contact

Thorsten Eggert


Alfred-Nobel-Straße 10
40789 Monheim am Rhein

In portfolio

22. Aug 2007 – 01. Aug 2017



Kay G. Balster

Principal / Authorized signatory